These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 15859111)
1. The EU-project ERAPharm. Incentives for the further development of guidance documents? Knacker T; Duis K; Ternes T; Fenner K; Escher B; Schmitt H; Römbke J; Garric J; Hutchinson T; Boxall AB Environ Sci Pollut Res Int; 2005; 12(2):62-5. PubMed ID: 15859111 [TBL] [Abstract][Full Text] [Related]
2. Sources, pathways, and relative risks of contaminants in surface water and groundwater: a perspective prepared for the Walkerton inquiry. Ritter L; Solomon K; Sibley P; Hall K; Keen P; Mattu G; Linton B J Toxicol Environ Health A; 2002 Jan; 65(1):1-142. PubMed ID: 11809004 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of measured and predicted environmental concentrations of selected human pharmaceuticals and personal care products. Liebig M; Moltmann JF; Knacker T Environ Sci Pollut Res Int; 2006 Mar; 13(2):110-9. PubMed ID: 16612900 [TBL] [Abstract][Full Text] [Related]
4. Pharmaceuticals in the environment in Italy: causes, occurrence, effects and control. Zuccato E; Castiglioni S; Fanelli R; Reitano G; Bagnati R; Chiabrando C; Pomati F; Rossetti C; Calamari D Environ Sci Pollut Res Int; 2006 Jan; 13(1):15-21. PubMed ID: 16417127 [TBL] [Abstract][Full Text] [Related]
5. Occurrence and fate of micropollutants in the Vidy Bay of Lake Geneva, Switzerland. Part I: priority list for environmental risk assessment of pharmaceuticals. Perazzolo C; Morasch B; Kohn T; Magnet A; Thonney D; Chèvre N Environ Toxicol Chem; 2010 Aug; 29(8):1649-57. PubMed ID: 20821616 [TBL] [Abstract][Full Text] [Related]
6. Ranking and prioritizing pharmaceuticals in the aquatic environment of China. Li Y; Zhang L; Liu X; Ding J Sci Total Environ; 2019 Mar; 658():333-342. PubMed ID: 30579191 [TBL] [Abstract][Full Text] [Related]
7. Targeting the environmental risk assessment of pharmaceuticals: Facts and fantasies. Tarazona JV; Escher BI; Giltrow E; Sumpter J; Knacker T Integr Environ Assess Manag; 2010 Jul; 6 Suppl():603-13. PubMed ID: 19886731 [TBL] [Abstract][Full Text] [Related]
8. The European Union Water Framework Directive (2000). Prescrire Int; 2013 Feb; 22(135):53. PubMed ID: 23444513 [TBL] [Abstract][Full Text] [Related]
9. Human pharmaceuticals in surface waters. Implementation of a prioritization methodology and application to the French situation. Besse JP; Garric J Toxicol Lett; 2008 Jan; 176(2):104-23. PubMed ID: 18077113 [TBL] [Abstract][Full Text] [Related]
10. Occurrence patterns of pharmaceuticals in water and wastewater environments. Nikolaou A; Meric S; Fatta D Anal Bioanal Chem; 2007 Feb; 387(4):1225-34. PubMed ID: 17205270 [TBL] [Abstract][Full Text] [Related]
11. Occurrence and ecotoxicological assessment of pharmaceuticals: Is there a risk for the Mediterranean aquatic environment? Desbiolles F; Malleret L; Tiliacos C; Wong-Wah-Chung P; Laffont-Schwob I Sci Total Environ; 2018 Oct; 639():1334-1348. PubMed ID: 29929299 [TBL] [Abstract][Full Text] [Related]
12. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001. Straub JO Toxicol Lett; 2002 Oct; 135(3):231-7. PubMed ID: 12270681 [TBL] [Abstract][Full Text] [Related]
13. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001. Straub JO Toxicol Lett; 2002 May; 131(1-2):137-43. PubMed ID: 11988366 [TBL] [Abstract][Full Text] [Related]
14. A broad spectrum analytical scheme for the screening of endocrine disruptors (EDs), pharmaceuticals and personal care products in wastewaters and natural waters. Bruchet A; Prompsy C; Fillppi G; Souall A Water Sci Technol; 2002; 46(3):97-104. PubMed ID: 12227610 [TBL] [Abstract][Full Text] [Related]
15. An international conference on "Pharmaceuticals in the Environment" in a frame of EU Knappe project. Roig B; Greenwood R; Barcelo D Environ Int; 2009 Jul; 35(5):763-5. PubMed ID: 19246093 [No Abstract] [Full Text] [Related]
16. Prioritizing human pharmaceuticals for ecological risks in the freshwater environment of Korea. Ji K; Han EJ; Back S; Park J; Ryu J; Choi K Environ Toxicol Chem; 2016 Apr; 35(4):1028-36. PubMed ID: 26348846 [TBL] [Abstract][Full Text] [Related]
17. Expert stakeholders' views on the management of human pharmaceuticals in the environment. Doerr-MacEwen NA; Haight ME Environ Manage; 2006 Nov; 38(5):853-66. PubMed ID: 16955232 [TBL] [Abstract][Full Text] [Related]
18. Hindsight rather than foresight: reality versus the EU draft guideline on pharmaceuticals in the environment. O'Brien E; Dietrich DR Trends Biotechnol; 2004 Jul; 22(7):326-30. PubMed ID: 15245903 [TBL] [Abstract][Full Text] [Related]
19. Why regulatory indifference towards pharmaceutical pollution of the environment could be a missed opportunity in public health protection. a holistic view. Kamba PF; Kaggwa B; Munanura EI; Okurut T; Kitutu FE Pan Afr Med J; 2017; 27():77. PubMed ID: 28819498 [TBL] [Abstract][Full Text] [Related]
20. Environmental Transformation of Pharmaceutical Formulations: A Scientific Review. Parezanović GŠ; Lalic-Popovic M; Golocorbin-Kon S; Vasovic V; Milijašević B; Al-Salami H; Mikov M Arch Environ Contam Toxicol; 2019 Aug; 77(2):155-161. PubMed ID: 31168646 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]